FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2495891008> ?p ?o ?g. }

• W2495891008 abstract "Background Idiopathic Parkinson's disease (IPD) is a neurodegenerative disorder, with the severity of the disability usually increasing with disease duration. IPD affects patients' health‐related quality of life, disability, and impairment. Current rehabilitation approaches have limited effectiveness in improving outcomes in patients with IPD, but a possible adjunct to rehabilitation might be non‐invasive brain stimulation by transcranial direct current stimulation (tDCS) to modulate cortical excitability, and hence to improve these outcomes in IPD. Objectives To assess the effectiveness of tDCS in improving motor and non‐motor symptoms in people with IPD. Search methods We searched the following databases (until February 2016): the Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library ; 2016 , Issue 2), MEDLINE, EMBASE, CINAHL, AMED, Science Citation Index, the Physiotherapy Evidence Database (PEDro), Rehabdata, and Inspec. In an effort to identify further published, unpublished, and ongoing trials, we searched trial registers and reference lists, handsearched conference proceedings, and contacted authors and equipment manufacturers. Selection criteria We included only randomised controlled trials (RCTs) and randomised controlled cross‐over trials that compared tDCS versus control in patients with IPD for improving health‐related quality of life , disability, and impairment. Data collection and analysis Two review authors independently assessed trial quality (JM and MP) and extracted data (BE and JM). If necessary, we contacted study authors to ask for additional information. We collected information on dropouts and adverse events from the trial reports. Main results We included six trials with a total of 137 participants. We found two studies with 45 participants examining the effects of tDCS compared to control (sham tDCS) on our primary outcome measure, impairment, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS). There was very low quality evidence for no effect of tDCS on change in global UPDRS score ( mean difference (MD) ‐7.10 %, 95% confidence interval (CI ‐19.18 to 4.97; P = 0.25, I² = 21%, random‐effects model). However, there was evidence of an effect on UPDRS part III motor subsection score at the end of the intervention phase (MD ‐14.43%, 95% CI ‐24.68 to ‐4.18; P = 0.006, I² = 2%, random‐effects model; very low quality evidence). One study with 25 participants measured the reduction in off and on time with dyskinesia, but there was no evidence of an effect (MD 0.10 hours, 95% CI ‐0.14 to 0.34; P = 0.41, I² = 0%, random‐effects model; and MD 0.00 hours, 95% CI ‐0.12 to 0.12; P = 1, I² = 0%, random‐ effects model, respectively; very low quality evidence). Two trials with a total of 41 participants measured gait speed using measures of timed gait at the end of the intervention phase, revealing no evidence of an effect ( standardised mean difference (SMD) 0.50, 95% CI ‐0.17 to 1.18; P = 0.14, I² = 11%, random‐effects model; very low quality evidence). Another secondary outcome was health‐related quality of life and we found one study with 25 participants reporting on the physical health and mental health aspects of health‐related quality of life (MD 1.00 SF‐12 score, 95% CI ‐5.20 to 7.20; I² = 0%, inverse variance method with random‐effects model; very low quality evidence; and MD 1.60 SF‐12 score, 95% CI ‐5.08 to 8.28; I² = 0%, inverse variance method with random‐effects model; very low quality evidence, respectively). We found no study examining the effects of tDCS for improving activities of daily living. In two of six studies, dropouts , adverse events, or deaths occurring during the intervention phase were reported. There was insufficient evidence that dropouts , adverse effects, or deaths were higher with intervention (risk difference (RD) 0.04, 95% CI ‐0.05 to 0.12; P = 0.40, I² = 0%, random‐effects model; very low quality evidence). We found one trial with a total of 16 participants examining the effects of tDCS plus movement therapy compared to control (sham tDCS) plus movement therapy on our secondary outcome, gait speed at the end of the intervention phase, revealing no evidence of an effect (MD 0.05 m/s, 95% CI ‐0.15 to 0.25; inverse variance method with random‐effects model; very low quality evidence). We found no evidence of an effect regarding differences in dropouts and adverse effects between intervention and control groups (RD 0.00, 95% CI ‐0.21 to 0.21; Mantel‐Haenszel method with random‐effects model; very low quality evidence). Authors' conclusions There is insufficient evidence to determine the effects of tDCS for reducing off time ( when the symptoms are not controlled by the medication) and on time with dyskinesia ( time that symptoms are controlled but the person still experiences involuntary muscle movements ) , and for improving health‐ related quality of life, disability, and impairment in patients with IPD. Evidence of very low quality indicates no difference in dropouts and adverse events between tDCS and control groups." @default.
• W2495891008 created "2016-08-23" @default.
• W2495891008 creator A5013481610 @default.
• W2495891008 creator A5057683138 @default.
• W2495891008 creator A5063870811 @default.
• W2495891008 creator A5071524221 @default.
• W2495891008 date "2016-07-18" @default.
• W2495891008 modified "2023-10-17" @default.
• W2495891008 title "Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease" @default.
• W2495891008 cites W1518820299 @default.
• W2495891008 cites W1600440343 @default.
• W2495891008 cites W1855371659 @default.
• W2495891008 cites W1856000993 @default.
• W2495891008 cites W1907035247 @default.
• W2495891008 cites W1943537685 @default.
• W2495891008 cites W1960242501 @default.
• W2495891008 cites W1969341878 @default.
• W2495891008 cites W1983936841 @default.
• W2495891008 cites W1985182010 @default.
• W2495891008 cites W1994908460 @default.
• W2495891008 cites W1995765794 @default.
• W2495891008 cites W2000557564 @default.
• W2495891008 cites W2007021711 @default.
• W2495891008 cites W2008560062 @default.
• W2495891008 cites W2009790328 @default.
• W2495891008 cites W2016612270 @default.
• W2495891008 cites W2021596556 @default.
• W2495891008 cites W2025995993 @default.
• W2495891008 cites W2034488360 @default.
• W2495891008 cites W2037142665 @default.
• W2495891008 cites W2039688993 @default.
• W2495891008 cites W2057180929 @default.
• W2495891008 cites W2061785440 @default.
• W2495891008 cites W2064963539 @default.
• W2495891008 cites W2064996887 @default.
• W2495891008 cites W2073205519 @default.
• W2495891008 cites W2078901487 @default.
• W2495891008 cites W2079890482 @default.
• W2495891008 cites W2081799512 @default.
• W2495891008 cites W2099262625 @default.
• W2495891008 cites W2101436214 @default.
• W2495891008 cites W2106631077 @default.
• W2495891008 cites W2116159247 @default.
• W2495891008 cites W2120749582 @default.
• W2495891008 cites W2121346930 @default.
• W2495891008 cites W2122085123 @default.
• W2495891008 cites W2123627348 @default.
• W2495891008 cites W2129241661 @default.
• W2495891008 cites W2129707336 @default.
• W2495891008 cites W2132862414 @default.
• W2495891008 cites W2134236426 @default.
• W2495891008 cites W2135640360 @default.
• W2495891008 cites W2135842106 @default.
• W2495891008 cites W2136570995 @default.
• W2495891008 cites W2140374231 @default.
• W2495891008 cites W2153238542 @default.
• W2495891008 cites W2158342248 @default.
• W2495891008 cites W2167289365 @default.
• W2495891008 cites W2196917261 @default.
• W2495891008 cites W2300876890 @default.
• W2495891008 cites W2402071138 @default.
• W2495891008 cites W2634872290 @default.
• W2495891008 cites W306755584 @default.
• W2495891008 cites W4232842600 @default.
• W2495891008 cites W4247791750 @default.
• W2495891008 cites W49024283 @default.
• W2495891008 cites W957725536 @default.
• W2495891008 doi "https://doi.org/10.1002/14651858.cd010916.pub2" @default.
• W2495891008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6457946" @default.
• W2495891008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27425786" @default.
• W2495891008 hasPublicationYear "2016" @default.
• W2495891008 type Work @default.
• W2495891008 sameAs 2495891008 @default.
• W2495891008 citedByCount "28" @default.
• W2495891008 countsByYear W24958910082016 @default.
• W2495891008 countsByYear W24958910082017 @default.
• W2495891008 countsByYear W24958910082018 @default.
• W2495891008 countsByYear W24958910082019 @default.
• W2495891008 countsByYear W24958910082020 @default.
• W2495891008 countsByYear W24958910082021 @default.
• W2495891008 countsByYear W24958910082022 @default.
• W2495891008 countsByYear W24958910082023 @default.
• W2495891008 crossrefType "journal-article" @default.
• W2495891008 hasAuthorship W2495891008A5013481610 @default.
• W2495891008 hasAuthorship W2495891008A5057683138 @default.
• W2495891008 hasAuthorship W2495891008A5063870811 @default.
• W2495891008 hasAuthorship W2495891008A5071524221 @default.
• W2495891008 hasBestOaLocation W24958910082 @default.
• W2495891008 hasConcept C118552586 @default.
• W2495891008 hasConcept C126322002 @default.
• W2495891008 hasConcept C159110408 @default.
• W2495891008 hasConcept C168563851 @default.
• W2495891008 hasConcept C17744445 @default.
• W2495891008 hasConcept C1862650 @default.
• W2495891008 hasConcept C197934379 @default.
• W2495891008 hasConcept C199539241 @default.
• W2495891008 hasConcept C24998067 @default.
• W2495891008 hasConcept C27415008 @default.
• W2495891008 hasConcept C2776478404 @default.
• W2495891008 hasConcept C2777803708 @default.

• next